HOOK hookipapharma.com: Forward P/S Multiple
HOOKIPA Pharma Inc. (HOOK) automates the creation of immunotherapeutic vectors via closed bioreactors. On GURU.Markets, the forward P/S valuation reflects the price action, where 0.90 characterizes this valuation parameter. The company relies on partnerships with industry behemoths due to a lack of profitability. Vaccine development is limited by the R&D sector and strict FDA oversight, which determines the overall financial stability of the business.
Metric breakdowns and analytics for hookipapharma.com (HOOK)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- debt and solvency information:
Debt to Equity HOOKIPA Pharma Inc.|HOOK - Long-Term Debt to Capital|Short-Term Debt to Capital HOOKIPA Pharma|HOOK - Company Total Debt Obligations|Debt to Book Capitalization Ratio HOOKIPA Pharma Inc.|HOOK - Long-Term Liabilities|Company Short-Term Debts HOOKIPA Pharma|Quick Liquidity Indicator hookipapharma.com
- business earnings and investment ratios data:
HOOK - Final Profit|Expected Profit HOOKIPA Pharma Inc.|HOOK - Market Cap to Net Income|Forward P/E Multiple HOOKIPA Pharma|HOOK - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple HOOKIPA Pharma Inc.|HOOK - Operating profit EBITDA|Earnings per share for the last twelve months HOOKIPA Pharma|HOOK - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months hookipapharma.com|HOOK - Net earnings per share growth this year|Earnings growth forecast for next year HOOKIPA Pharma Inc.
- revenue and sales details:
Comprehensive company analysis:HOOK (HOOKIPA)
This indicator determines the asset's market value relative to its projected revenue, allowing for an assessment of the fairness of the control premium and preventing illusions during local price spikes. By analyzing the expected P/S ratio, an investor can compare the current capitalization of HOOKIPA Pharma Inc. (HOOK) with the potential for vaccine commercialization and the scalability of viral vector production for mass cancer treatment.
Direct competitors
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|Abivax Corp - Forward P/S Multiple|Forward Price to Sales ADMA (ADMA Corp)|Protagonist Therapeutics (PTGX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio immunovant.com (IMVT)|Price-to-Projected Revenue Ratio Kiniksa|Market Cap to Future Revenue Ratio Grifols SA GRFS|Price-to-Projected Revenue Ratio Adaptive Biotechnologies Corp (ADPT)|Forward P/S Multiple Celldex Corp (CLDX)|Forward P/S Multiple AUPH (Aurinia Pharmaceuticals)|Market Cap to Expected Sales Ratio biocryst.com (BCRX)|VERA - Price-to-Projected Revenue Ratio|Future Price to Revenue DNTH|PHVS: Forward P/S Multiple|AbCellera Corp (ABCL) - Forward P/S Multiple|Forward Price-to-Revenue Multiple TRML|PGEN: Forward Price to Sales|Price-to-Projected Revenue Ratio Pharming Group (PHAR)|NKTR: Future Price to Revenue|Forward P/S Multiple UPB (Upstream Bio Corp)|Forward Price to Sales ZBIO|Immunome, Inc. - Forward P/S Multiple|GOSS - Forward P/S Multiple|KalVista Pharmaceuticals, Inc. (KALV) - Price-to-Projected Revenue Ratio|Septerna, Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Pieris Pharmaceuticals Inc|Forward Price-to-Revenue Multiple Savara Pharma (SVRA)|Forward P/S Multiple RIGL|Forward P/S Multiple anaptysbio.com (ANAB)|Astria Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales ENGN|RAPT Therapeutics, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio Aerovate Therapeutics Inc JBIO|Aclaris Therapeutics (ACRS) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue KYTX|TLSA (Tiziana Life Sciences Ltd) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Cabaletta Bio Inc. (CABA)|Forward Price-to-Revenue Multiple VTYX (Ventyx Bio)|Market Cap to Expected Sales Ratio Theratechnologies, Inc|Forward P/S Multiple AVTX (Avalo Therapeutics, Inc)|Forward Price to Sales ELDN|AGEN - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Climb Bio Inc.|Zura Bio Limited (ZURA) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio aTyr Pharmaceuticals (ATYR)|Price-to-Projected Revenue Ratio Adagene Inc|Forward P/S Multiple Ikena Oncology, Inc.|Price-to-Projected Revenue Ratio Shattuck Labs, Inc. (STTK)|EQ: Future Price to Revenue|Forward P/S Multiple CNTB (Connect Biopharma Holdings Limited)|Forward Price to Sales IMUX|Atara Biotherapeutics Inc - Forward P/S Multiple|IFRX - Forward P/S Multiple|X4 Pharmaceuticals, Inc. (XFOR) - Price-to-Projected Revenue Ratio|Adicet Bio, Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Celularity Inc|Forward Price-to-Revenue Multiple INmune Bio Corporation (INMB)|Forward P/S Multiple BRNS|Forward P/S Multiple kezarlifesciences.com (KZR)|SAB Biotherapeutics, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales AKTX|Enlivex Therapeutics, Ltd. - Forward P/S Multiple|Market Cap to Expected Sales Ratio Q32 Bio Inc. QTTB|GeoVax Labs, Inc. (GOVX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple edesabiotech.com|Price-to-Projected Revenue Ratio iBio|Forward Price-to-Revenue Multiple Carisma Tx (CARM)|Forward Price-to-Revenue Multiple XTLB (XTL Biopharmaceuticals, Ltd.)|Forward P/S Multiple boltbio.com (BOLT)|Price-to-Projected Revenue Ratio HCW Biologics HCWB|APVO: Market Cap to Projected Revenue|AIM ImmunoTech - Forward P/S Multiple|Market Cap to Future Revenue Ratio Aditxt|GRI: Forward P/S Multiple|XORTX Corp - Forward Price to Sales|Price-to-Projected Revenue Ratio Vyome Holdings Inc|Market Cap to Future Revenue Ratio revbiosciences.com REVB|Price-to-Projected Revenue Ratio Indaptus Therapeutics, Inc. (INDP)|SCNI - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio CalciMedica CALI|Forward P/S Multiple Affimed NV AFMD|Allakos Therapeutics - Forward P/S Multiple|Market Cap to Expected Sales Ratio IGM Biosciences, Inc. IGMS|iTeos Therapeutics, Inc. (ITOS) - Price-to-Projected Revenue Ratio|Future Price to Revenue OCEA (Ocean Biomedical Inc)|TCBP (TC BioPharm (Holdings) PLC) - Forward P/S Multiple|Forward P/S Multiple Third Harmonic Bio Inc
